SCHEMBL14744488

SCHEMBL14744488

CC[C@@H](C(=O)O)[C@H](C)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.42
CHRM1 P11229 1/20 0.42
AKR1A1 P14550 1/20 0.42
CHRM3 P20309 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
ADRA1A P35348 1/20 0.42
HRH1 P35367 1/20 0.42
DRD3 P35462 1/20 0.42
SLC6A3 Q01959 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
SLC1A3 P43003 2/20 0.39
SLC1A2 P43004 2/20 0.39
SLC1A1 P43005 2/20 0.39
TP53 P04637 1/20 0.38
CA2 P00918 1/20 0.36
MAPK1 P28482 1/20 0.36
ALDH1A1 P00352 1/20 0.34
ACE P12821 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1604899 1.00 TDP1 (0.42) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL14186592 1.00 TDP1 (0.42) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL28194808 0.97 TDP1 (0.40) TDP1CHRM1AKR1A1CHRM3HTR2A
Maleic Acid SCHEMBL29176648 0.89 TSHR (0.39) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL21496160 0.85 TDP1 (0.41) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL2405893 0.85 SLC1A3 (0.39) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL8581725 0.84 TDP1 (0.39) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL13889788 0.82 TDP1 (0.37) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL11936620 0.82 TDP1 (0.37) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL1299794 0.82 CHRM1 (0.37) TDP1CHRM1AKR1A1CHRM3HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2751059-B1 PROCESS FOR PREPARING DI-SUBSTITUTED SUCCINATES SAUDI BASIC IND CORP (SA) 2015-09-16 EP disclosed
US-8889898-B2 Process for preparing di-substituted succinates SAUDI BASIC INDUSTRIES CORPORATION (SA) 2014-11-18 US disclosed
US-20140194647-A1 PROCESS FOR PREPARING DI-SUBSTITUTED SUCCINATES SAUDI BASIC INDUSTRIES CORPORATION (SA) 2014-07-10 US disclosed
EP-2751059-A1 PROCESS FOR PREPARING DI-SUBSTITUTED SUCCINATES Saudi Basic Industries Corporation (SA) 2014-07-09 EP disclosed
WO-2013029767-A1 PROCESS FOR PREPARING DI-SUBSTITUTED SUCCINATES SAUDI BASIC INDUSTRIES CORPORATION (SA) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194647-A1 PROCESS FOR PREPARING DI-SUBSTITUTED SUCCINATES TKT, TALDO1, MPST TDP1 3580/4885CHRM1 3739/4885AKR1A1 425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.